BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.45−0.16 (-2.10%)
Close on Nov 16, 2026Market cap $1.90BP/E –Yield –
BioCryst Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
BioCryst Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -37.4%. For fiscal 2025 it was 30.2%, against -19.7% the year before. The highest annual figure on record is 30.2% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.2% | +49.9 |
| FY2024 | Dec 31, 2024 | -19.7% | +48.6 |
| FY2023 | Dec 31, 2023 | -68.4% | +22.9 |
| FY2022 | Dec 31, 2022 | -91.2% | +25.9 |
| FY2021 | Dec 31, 2021 | -117.1% | +909.2 |
| FY2020 | Dec 31, 2020 | -1026.4% | −803.4 |
| FY2019 | Dec 31, 2019 | -223.0% | +267.3 |
| FY2018 | Dec 31, 2018 | -490.3% | −229.1 |
| FY2017 | Dec 31, 2017 | -261.2% | −51.9 |
| FY2016 | Dec 31, 2016 | -209.3% | −120.1 |
| FY2015 | Dec 31, 2015 | -89.1% | +242.9 |
| FY2014 | Dec 31, 2014 | -332.1% | −158.4 |
| FY2013 | Dec 31, 2013 | -173.7% | −25.1 |
| FY2012 | Dec 31, 2012 | -148.6% | +141.3 |
| FY2011 | Dec 31, 2011 | -289.9% | −235.6 |
| FY2010 | Dec 31, 2010 | -54.3% | −36.2 |
| FY2009 | Dec 31, 2009 | -18.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 21.0% | +12.9 |
| Q2 FY2026 | Jun 30, 2026 | 35.9% | +32.8 |
| Q1 FY2026 | Mar 31, 2026 | -461.5% | −461.5 |
| Q4 FY2025 | Dec 31, 2025 | 60.5% | +80.8 |
| Q3 FY2025 | Sep 30, 2025 | 8.1% | +20.1 |
| Q2 FY2025 | Jun 30, 2025 | 3.1% | +14.7 |
| Q1 FY2025 | Mar 31, 2025 | 0.0% | +38.2 |
| Q4 FY2024 | Dec 31, 2024 | -20.4% | +45.7 |
| Q3 FY2024 | Sep 30, 2024 | -12.0% | +29.7 |
| Q2 FY2024 | Jun 30, 2024 | -11.6% | +79.7 |
| Q1 FY2024 | Mar 31, 2024 | -38.1% | +39.4 |
| Q4 FY2023 | Dec 31, 2023 | -66.1% | +23.8 |
| Q3 FY2023 | Sep 30, 2023 | -41.7% | +14.4 |
| Q2 FY2023 | Jun 30, 2023 | -91.3% | −1.5 |
| Q1 FY2023 | Mar 31, 2023 | -77.5% | +71.1 |
| Q4 FY2022 | Dec 31, 2022 | -89.9% | −52.2 |
| Q3 FY2022 | Sep 30, 2022 | -56.1% | +87.4 |
| Q2 FY2022 | Jun 30, 2022 | -89.8% | −3.4 |
| Q1 FY2022 | Mar 31, 2022 | -148.6% | +188.7 |
| Q4 FY2021 | Dec 31, 2021 | -37.7% | +1468.6 |
| Q3 FY2021 | Sep 30, 2021 | -143.4% | +612.3 |
| Q2 FY2021 | Jun 30, 2021 | -86.5% | +1258.3 |
| Q1 FY2021 | Mar 31, 2021 | -337.3% | +442.3 |
| Q4 FY2020 | Dec 31, 2020 | -1506.3% | −1499.7 |
| Q3 FY2020 | Sep 30, 2020 | -755.7% | +1362.1 |
| Q2 FY2020 | Jun 30, 2020 | -1344.7% | +1254.0 |
| Q1 FY2020 | Mar 31, 2020 | -779.6% | −252.1 |
| Q4 FY2019 | Dec 31, 2019 | -6.6% | +998.6 |
| Q3 FY2019 | Sep 30, 2019 | -2117.9% | −82.3 |
| Q2 FY2019 | Jun 30, 2019 | -2598.7% | −2451.0 |
| Q1 FY2019 | Mar 31, 2019 | -527.5% | +120.8 |
| Q4 FY2018 | Dec 31, 2018 | -1005.2% | −502.8 |
| Q3 FY2018 | Sep 30, 2018 | -2035.6% | −1862.8 |
| Q2 FY2018 | Jun 30, 2018 | -147.6% | +397.2 |
| Q1 FY2018 | Mar 31, 2018 | -648.3% | −497.6 |
| Q4 FY2017 | Dec 31, 2017 | -502.4% | −452.3 |
| Q3 FY2017 | Sep 30, 2017 | -172.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -544.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -150.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -50.1% | – |
See a number that looks wrong?